Functionalized upconversion nanoparticles for targeted labelling of bladder cancer cells

Dmitry Polikarpov, Liuen Liang, Andrew Care, Anwar Sunna, Douglas Campbell, Bradley Walsh, Irina Balalaeva, Andrei Zvyagin, David Gillatt, Evgenii Guryev

Research output: Contribution to journalArticle

1 Citation (Scopus)
4 Downloads (Pure)

Abstract

Bladder cancer is the ninth most common cancer worldwide. Due to a high risk of recurrence and progression of bladder cancer, every patient needs long-term surveillance, which includes regular cystoscopy, sometimes followed by a biopsy of suspicious lesions or resections of recurring tumours. This study addresses the development of novel biohybrid nanocomplexes representing upconversion nanoparticles (UCNP) coupled to antibodies for photoluminescent (PL) detection of bladder cancer cells. Carrying specific antibodies, these nanoconjugates selectively bind to urothelial carcinoma cells and make them visible by emitting visible PL upon excitation with deeply penetrating near-infrared light. UCNP were coated with a silica layer and linked to anti-Glypican-1 antibody MIL38 via silica-specific solid-binding peptide. Conjugates have been shown to specifically attach to urothelial carcinoma cells with high expression of Glypican-1. This result highlights the potential of produced conjugates and conjugation technology for further studies of their application in the tumour detection and fluorescence-guided resection.
Original languageEnglish
Article number820
Pages (from-to)1-11
Number of pages11
JournalBiomolecules
Volume9
Issue number12
DOIs
Publication statusPublished - 3 Dec 2019

    Fingerprint

Bibliographical note

Copyright the Author(s) 2019. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • upconversion nanoparticles
  • photoluminescent nanocomplexes
  • bladder cancer
  • solid-binding peptide
  • glypican-1
  • photodynamic diagnostics

Cite this